Drawing based on the label description. No photo yet.
“Dapagliflozin and metformin hydrochloride extended-release tablets are available as follows: 5 mg/500 mg tablets are orange, biconvex, capsule-shaped film-coated tablets debossed with "D/M" on one side and "5/500" on other side, may have matt finish appearance”
D M 5 500 pill
Pill with imprint D M 5 500 is orange, capsule, 20 mm and has been identified as Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg. It is used for type 2 diabetes and heart failure. It is supplied by Ascend Laboratories, LLC.
Dapagliflozin and Metformin Hydrochloride 5 mg / 500 mg
- Imprint
- D M 5 500
- Strength
- Dapagliflozin 5 mg / Metformin Hydrochloride 500 mg
- Used for
- Type 2 diabetes and heart failure
- Color
- Orange
- Shape
- Capsule / oblong
- Size
- 20 mm
- Score
- No score line
- Form
- Tablet, film coated, extended release
- Manufacturer
- Ascend Laboratories, LLC
- Drug class
- Diabetes medicine (SGLT2 inhibitor)
- NDC
- 67877-619, 67877-619-30, 67877-619-05
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Dapagliflozin and Metformin used for?
Dapagliflozin and Metformin is used for type 2 diabetes and heart failure.
- Medicine type
- Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label
Dapagliflozin and metformin hydrochloride extended-release tablets are a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin, when used as a component of dapagliflozin and metformin hydrochloride extended-release tablets, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:
- Sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
- CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure.
- Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
Limitations of Use
- Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
- Because of the metformin hydrochloride component, the use of dapagliflozin and metformin hydrochloride extended-release tablets is limited to patients with type 2 diabetes mellitus for all indications.
- Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Dapagliflozin and metformin hydrochloride extended-release tablets are not expected to be effective in these populations.
Pediatric use information is approved for AstraZeneca AB’s Xigduo ® XR (dapagliflozin and metformin hydrochloride) Extended-Release Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.
From the FDA-approved label on DailyMed (published Sep 24, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows D/M and the other side shows 5/500.
- It is orange, capsule, 20 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Dapagliflozin, Metformin Hydrochloride
Inactive: Lactose Monohydrate, Microcrystalline Cellulose, Low-Substituted Hydroxypropyl Cellulose (11% Hydroxypropyl, 130000 Mw), Hypromellose 2910 (3 Mpa.s), Silicon Dioxide, Magnesium Stearate, Copovidone, Povidone K90, Carboxymethylcellulose Sodium, Unspecified, Polyvinyl Alcohol, Unspecified, Talc, Titanium Dioxide, Glyceryl Monocaprylocaprate, Sodium Lauryl Sulfate, Fd&c Yellow No. 6
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
G 369
Topiramate 100 mg
Gray & orange, capsule, 19 mm
Used for bipolar disorder and focal seizures
-
SD TC 5 mg
Tacrolimus 5 mg
Orange, capsule, 21 mm
Used for eczema
-
G 582
Fenofibrate 200 mg
Orange, capsule, 19 mm
Used for high cholesterol and high triglycerides
-
LA 47
Pregabalin 225 mg
Orange & white, capsule, 19 mm
Used for seizures and nerve pain after shingles
Schedule V
-
720
Budesonide 3 mg
Orange & white, capsule, 19 mm
Used for inflammatory bowel disease and year-round allergies
-
C248
Darunavir 600 mg
Orange, capsule, 21 mm
Used for HIV
Other Dapagliflozin and Metformin pills
- 1073 10 1000 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- N 25 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- D M 10 1000 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- MD4 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Brown, oval, 20 mm Used for type 2 diabetes and heart failure
- RL 61 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- L111 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- F26 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 20 mm Used for type 2 diabetes and heart failure
- DM4 Dapagliflozin and Metformin Hydrochloride 10 mg / 1000 mg Yellow, oval, 21 mm Used for type 2 diabetes and heart failure